E. Strong (ed.). Gastric cancer. Principles and practice. Springer (2015)
The majority of patients with gastric cancer present with advanced disease, which is incurable. Molecularly targeted therapies, such as those targeting HER2, are anticipated to improve the current status of systemic treatment beyond conventional cytotoxic therapy. Trastuzumab in combination with chemotherapy in patients is the first molecular agent in metastatic HER2positive gastric and gastroesophageal to result in improvements in response rates, time to progression and survival. Trastuzumab is now being investigated in the neoadjuvant and adjuvant setting. Unfortunately, as with breast cancer, many esophagogastric patients will develop resistance to trastuzumab. Several promising therapeutic agents are currently under investigation as monotherapy and in combination with chemotherapy in the first and second line setting. New avenues of research into mechanisms of resistance and technology to better diagnose and treat HER2 gastric cancer are being actively studied.
[contact-form-7 id=»5168″ title=»Контактная форма 1″]